Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.63 |
| ▸ | NCF1 | P14598 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | ILK | Q13418 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637564 | 0.96 | EGFR (0.69) | EGFRNCF1APPILKKDM1A | |
| SCHEMBL29831918 | 0.81 | EGFR (0.59) | EGFRNCF1KDM4EMAPK1TDP1 | |
| SCHEMBL30504578 | 0.79 | EGFR (0.70) | EGFRNCF1MAPT | |
| SCHEMBL4649110 | 0.79 | EGFR (0.70) | EGFRNCF1MAPT | |
| SCHEMBL30241125 | 0.78 | EGFR (1.00) | EGFRKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29517021 | 0.78 | EGFR (1.00) | EGFRKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL668493 | 0.78 | EGFR (1.00) | EGFRKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6489451 | 0.77 | EGFR (0.59) | EGFRNCF1TDP1NPC1MAPT | |
| Hydrochloric Acid SCHEMBL28023744 | 0.77 | EGFR (0.96) | EGFRKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5682759 | 0.75 | EGFR (0.56) | EGFRNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |